Skip to Main Content

Paper Details

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Cancer Discov
89
2021
ERBB2, ERBB2 nonamplified cancer cells, ERBB2 nonamplified cells, Early-Stage, HER2, HER2-Positive Breast Cancer, HER2-positive breast cancer, HER2-positive early, Pertuzumab, T-DM1, breast cancer, patients, pertuzumab, trastuzumab emtansine, tumor, tumor cells
Author NameAffiliation
Ingrid A MayerVanderbilt-Ingram Cancer Center
Aditya BardiaMassachusetts General Hospital
Tari A KingDana-Farber/Brigham and Women's Cancer Center
Tari A KingBrigham and Women's Hospital
Kornelia PolyakDana-Farber Cancer Institute, Harvard Medical School
Kornelia PolyakCenter for Cancer Evolution, Dana-Farber Cancer Institute
Kornelia Polyak
Kornelia PolyakDana-Farber Cancer Institute, Harvard Medical School
Kornelia Polyak
Kornelia PolyakCenter for Cancer Evolution, Dana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute, Harvard Medical School
Eric P WinerDana-Farber/Brigham and Women's Cancer Center
Ian E KropDana-Farber Cancer Institute, Harvard Medical School
Ian E KropDana-Farber/Brigham and Women's Cancer Center
  • 1 - 14

Datasets

Release 1.2